We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Fortive Corporation (FTV - Free Report) recently reported preliminary expected third-quarter 2020 results. The company is expected to release full financial results for the period soon.
Encouraging Q3 Preliminary Projections
For third-quarter 2020, the company expects total revenues to increase 2% year over year, which is above the guidance provided earlier.
The Zacks Consensus Estimate for revenues is currently pegged at $1.83 billion.
Notably, the company operates under the following two organized segments - Professional Instrumentation and Industrial Technologies.
For the quarter, Professional Instrumentation segment revenues are expected to increase 1% versus prior expectation of mid-single digit to low-single digit year-over-year decline.
Also, Industrial Technologies revenues are expected to increase 4.5% versus prior guidance of low-single digit year-over-year increase.
In addition to the above, Fortive anticipates positive year-over-year growth in both operating profit and adjusted operating profit for the quarter.
Management is optimistic about the quarterly results. Following the announcement, its shares gained 2.14% to close at $79.06 yesterday.
Moreover, the company has outperformed the industry over the past three months. The stock has gained 16.1% compared with 8.1% and 6.3% growth of the industry and S&P 500, respectively.
Positive Earnings Estimate Revision
Fortive has an impressive earnings surprise history. The company beat estimates in three of the trailing four quarters, with the average surprise being 6.6%.
Moreover, over the past 30 days, third-quarter estimates were revised upward by 7.8% to 83 cents per share. Also, for full-year 2020, estimates were upwardly revised by 2.8% to $3.25 per share.
Further, the company has a long-term expected EPS growth rate of 11.4%.
Long-term earnings growth rate of Dropbox, Etsy and Intuit is pegged at 34.4%, 26.5% and 12.3%, respectively.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Fortive Announces Encouraging Q3 Preliminary Expectations
Fortive Corporation (FTV - Free Report) recently reported preliminary expected third-quarter 2020 results. The company is expected to release full financial results for the period soon.
Encouraging Q3 Preliminary Projections
For third-quarter 2020, the company expects total revenues to increase 2% year over year, which is above the guidance provided earlier.
The Zacks Consensus Estimate for revenues is currently pegged at $1.83 billion.
Notably, the company operates under the following two organized segments - Professional Instrumentation and Industrial Technologies.
For the quarter, Professional Instrumentation segment revenues are expected to increase 1% versus prior expectation of mid-single digit to low-single digit year-over-year decline.
Also, Industrial Technologies revenues are expected to increase 4.5% versus prior guidance of low-single digit year-over-year increase.
In addition to the above, Fortive anticipates positive year-over-year growth in both operating profit and adjusted operating profit for the quarter.
Fortive Corporation Price and Consensus
Fortive Corporation price-consensus-chart | Fortive Corporation Quote
Share Price Movement
Management is optimistic about the quarterly results. Following the announcement, its shares gained 2.14% to close at $79.06 yesterday.
Moreover, the company has outperformed the industry over the past three months. The stock has gained 16.1% compared with 8.1% and 6.3% growth of the industry and S&P 500, respectively.
Positive Earnings Estimate Revision
Fortive has an impressive earnings surprise history. The company beat estimates in three of the trailing four quarters, with the average surprise being 6.6%.
Moreover, over the past 30 days, third-quarter estimates were revised upward by 7.8% to 83 cents per share. Also, for full-year 2020, estimates were upwardly revised by 2.8% to $3.25 per share.
Further, the company has a long-term expected EPS growth rate of 11.4%.
Zacks Rank & Other Key Picks
Currently, Fortive has a Zacks Rank #2 (Buy). Other top-ranked stocks in the broader technology sector include Dropbox (DBX - Free Report) , Etsy, Inc. (ETSY - Free Report) and Intuit Inc. (INTU - Free Report) , each carrying a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Long-term earnings growth rate of Dropbox, Etsy and Intuit is pegged at 34.4%, 26.5% and 12.3%, respectively.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>